The Evolution of Natriuretic Peptide Augmentation in Management of Heart Failure and the Role of Sacubitril/valsartan

Authors

Srikanth Yandrapalli
Wilbert Aronow, New York Medical CollegeFollow
P Mondal
D Chabbott

DOI

10.5114/aoms.2017.68813

Journal Title

Archives of Medical Science : AMS

First Page

1207

Last Page

1216

Document Type

Article

Publication Date

8-1-2017

Department

Medicine

Abstract

Heart failure (HF) is one of the leading causes of morbidity, mortality, and health care expenditures in the US and worldwide. For three decades, the pillars of treatment of HF with reduced ejection fraction (HFrEF) were medications that targeted the sympathetic nervous system (SNS) and the renin-angiotensin-aldosterone system (RAAS). Prior attempts to augment the natriuretic peptide system (NPS) for the management of HF failed either due to lack of significant clinical benefit or due to the unacceptable side effect profile. This review article will discuss the NPS, the failure of early drugs which targeted the NPS as therapies for HF, and the sequence of events which led to the development of sacubitril plus valsartan (Entresto; LCZ696; Novartis). LCZ696 has been shown to be superior to the standard of care available for treatment of HFrEF in several substantial hard endpoints including heart failure hospitalizations, cardiovascular mortality, and all-cause mortality.

Recommended Citation

Yandrapalli, S., Aronow, W., Mondal, P., & Chabbott, D. (2017). The Evolution of Natriuretic Peptide Augmentation in Management of Heart Failure and the Role of Sacubitril/valsartan. Archives of Medical Science : AMS, 13 (5), 1207-1216. https://doi.org/10.5114/aoms.2017.68813

Publisher's Statement

Originally published in Archives of Medical Science 2017; 13, 5: 1207–1216. The original material can be found here.